Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Miles

Showing results (401-410 of 501) with videos related to

Pageof 51
Sort By:
International Journal of Cancer|May 14, 2026
Early-Life Exposures and Risk of Multiple Myeloma: A Population-Based Case-Control Study in AustraliaZhuoyu Sun, Julie K Bassett, Simon Cheah, et al.
Palliative & Supportive Care|October 10, 2019
A feasibility and acceptability study of an adaptation of the Mindful Self-Compassion program for adult cancer patientsJoanne Brooker, John Julian, Jeremy Millar, et al.
Biomarker Research|October 4, 2014
Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphomaFrancine Foss, Bertrand Coiffier, Steven Horwitz, et al.
The Medical Journal of Australia|May 4, 2005
The Australian Cancer Anaemia Survey: a snapshot of anaemia in adult patients with cancerTara Seshadri, H Miles Prince, David R Bell, et al.
Blood|March 15, 2003
Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced ageLinda Mileshkin, James J Biagi, Paul Mitchell, et al.
Internal Medicine Journal|April 24, 2023
Executive summary of consensus clinical practice guidelines for the prevention of infection in patients with multiple myelomaBenjamin W Teh, Gemma Reynolds, Monica A Slavin, et al.
Leukemia & Lymphoma|October 28, 2020
Efficacy and safety of weekly carfilzomib (70 mg/m<sup>2</sup>), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studiesXavier Leleu, Meral Beksac, Takaaki Chou, et al.
European Journal of Haematology|August 24, 2017
Distress and unmet needs during treatment and quality of life in early cancer survivorship: A longitudinal study of haematological cancer patientsDevesh V Oberoi, Victoria M White, John F Seymour, et al.
Blood|October 23, 2014
Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapyCharlotte F M Hughes, Amit Khot, Christopher McCormack, et al.
Internal Medicine Journal|August 5, 2025
Management of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation: position statement of the Medical and Scientific Advisory Group of Myeloma AustraliaGeorgia McCaughan, Hayley Beer, Christian Bryant, et al.
Pageof 51

Showing results (401-410 of 501) with videos related to

Sort By:
Pageof 51
International Journal of Cancer|May 14, 2026
Early-Life Exposures and Risk of Multiple Myeloma: A Population-Based Case-Control Study in AustraliaZhuoyu Sun, Julie K Bassett, Simon Cheah, et al.
Palliative & Supportive Care|October 10, 2019
A feasibility and acceptability study of an adaptation of the Mindful Self-Compassion program for adult cancer patientsJoanne Brooker, John Julian, Jeremy Millar, et al.
Biomarker Research|October 4, 2014
Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphomaFrancine Foss, Bertrand Coiffier, Steven Horwitz, et al.
The Medical Journal of Australia|May 4, 2005
The Australian Cancer Anaemia Survey: a snapshot of anaemia in adult patients with cancerTara Seshadri, H Miles Prince, David R Bell, et al.
Blood|March 15, 2003
Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced ageLinda Mileshkin, James J Biagi, Paul Mitchell, et al.
Internal Medicine Journal|April 24, 2023
Executive summary of consensus clinical practice guidelines for the prevention of infection in patients with multiple myelomaBenjamin W Teh, Gemma Reynolds, Monica A Slavin, et al.
Leukemia & Lymphoma|October 28, 2020
Efficacy and safety of weekly carfilzomib (70 mg/m<sup>2</sup>), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studiesXavier Leleu, Meral Beksac, Takaaki Chou, et al.
European Journal of Haematology|August 24, 2017
Distress and unmet needs during treatment and quality of life in early cancer survivorship: A longitudinal study of haematological cancer patientsDevesh V Oberoi, Victoria M White, John F Seymour, et al.
Blood|October 23, 2014
Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapyCharlotte F M Hughes, Amit Khot, Christopher McCormack, et al.
Internal Medicine Journal|August 5, 2025
Management of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation: position statement of the Medical and Scientific Advisory Group of Myeloma AustraliaGeorgia McCaughan, Hayley Beer, Christian Bryant, et al.
Pageof 51